Shattuck Labs, Inc. Class of Warrant or Right, Outstanding
Shattuck Labs, Inc. (STTK) had Class of Warrant or Right, Outstanding of 3.10 million shares as of 2025-06-30, per its 10-Q filed 2025-08-14.
Financial Statements › Notes › Other Liabilities
us-gaap:ClassOfWarrantOrRightOutstanding · last filed 2025-08-14
- 2025-06-30: Class of Warrant or Right, Outstanding 3.10M shares.
- 2025-03-31: Class of Warrant or Right, Outstanding 3.10M shares.
- 2024-12-31: Class of Warrant or Right, Outstanding 3.10M shares.
- 2024-09-30: Class of Warrant or Right, Outstanding 3.10M shares.
| Period end | Class of Warrant or Right, Outstanding |
|---|---|
| 2025-06-30 | 3.10M shares 10-Q · filed 2025-08-14 |
| 2025-03-31 | 3.10M shares 10-Q · filed 2025-05-01 |
| 2024-12-31 | 3.10M shares 10-K · filed 2025-03-27 |
| 2024-09-30 | 3.10M shares 10-Q · filed 2024-11-14 |
| 2024-06-30 | 3.10M shares 10-Q · filed 2024-08-01 |
| 2024-03-31 | 3.10M shares 10-Q · filed 2024-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |